ARBORXR
7.10.2021 16:55:09 CEST | Business Wire | Press release
ArborXR , the leading enterprise AR/VR device management and content distribution platform, and AR/VR solutions distributor, Matts Digital , today announced a partnership to provide frictionless extended reality (XR) solutions at scale in Europe and beyond. With ArborXR’s mobile device management (MDM) software, Matts Digital will help companies securely manage fleets of XR devices, deploy apps and files remotely, and control the in-headset user experience. The partnership illustrates an accelerated shift to remote work and training amid the pandemic.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211007005755/en/
According to Forbes , global spending on AR/VR rose to $12 billion in 2020, up 50 percent from 2019.
“ArborXR and Matts Digital share a mission to help companies use and scale XR technology with ease, while offering exceptional customer service,” said ArborXR Co-Founder Will Stackable. “By partnering with Matts Digital, ArborXR is able to help global enterprise companies succeed and increase efficiency through the power of XR. We’re thrilled to enter the European market and provide vital software to help companies deploy AR/VR with confidence.”
Matts Digital offers an extensive range of AR/VR products, in addition to unique XR technology professional services. By utilizing ArborXR’s software, Matts Digital will help companies manage thousands of devices with security and control.
“Matts Digital is pleased to work with ArborXR to offer best-in-class XR solutions for a variety of global companies. Together, we will help customers use XR devices with confidence and achieve our shared goal to increase the simplicity, security and efficiency of XR in the workplace,” Matts Digital President Stephane Courgeon said.
To learn more about ArborXR or Matts Digital, visit ArborXR.com or Matts-Digital.com .
About ArborXR
ArborXR is AR/VR mobile device management (MDM) software that allows enterprise companies to securely manage fleets of XR devices, deploy apps and files remotely, and control the in-headset experience. It is used by Fortune 500 companies, businesses, and hundreds of independent software vendors to seamlessly manage devices, enroll and provision headsets, deploy apps and files remotely, and lock down the user experience with kiosk mode and a multi-app launcher. Learn more about ArborXR and its recent completion of a Series A at ArborXR.com .
About Matts Digital
Matts Digital is a Value-Added distributor, specializing in Virtual Reality (VR) and Augmented Reality (AR) solutions. We offer a full range of headsets, peripherals, accessories and hygiene products, as well as unique professional services in this area. Our significant industrial and logistical capacity allows our customers to easily consider the deployment of their ARVR projects on a large scale, in France and abroad. Learn more at Matts-Digital.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211007005755/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pelago Bioscience Acquires RG Discovery, Forming an Integrated Drug Discovery Partner Spanning Biology and Chemistry15.6.2026 09:00:00 CEST | Press release
The combination unites Pelago Bioscience’s industry-leading and proprietary cellular target engagement capabilities with RG Discovery’s deep medicinal chemistry and custom synthesis expertise - enabling customers to advance drug discovery programs across the full design-make-test-analyze-(DMTA) cycle with a single specialist partner. Pelago Bioscience, a specialist drug discovery focused contract research organization (CRO), known for its industry-leading cell-based target engagement assays, is pleased to announce the acquisition of RG Discovery, and thereby adding deep expertise in medicinal chemistry, custom synthesis, and integrated drug discovery. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615340933/en/ Michael Dabrowski, Chief Executive Officer of Pelago Bioscience By combining Pelago Bioscience's biology-focused capabilities with RG Discovery's chemistry expertise, the enlarged platform will enable drug discover
LTM Launches BlueVerse™ for iRun to Outcreate Managed Services in the Agentic AI Era15.6.2026 08:10:00 CEST | Press release
AI-native operations model enables enterprises to move from reactive service delivery to intelligent, outcome-driven managed services LTM, the Business Creativity partner to the world’s largest enterprises, today announced the launch of BlueVerse™ for iRun, an AI-native managed services model designed to transform traditional IT operations into a resilient, intelligent, and outcome-driven operating model. As enterprise environments grow more complex—spanning hybrid cloud, SaaS, and AI-driven ecosystems—traditional managed services models are increasingly constrained by siloed teams, static processes, and effort-led scaling. BlueVerse for iRun addresses this shift by moving beyond headcount-based delivery to a platform-led approach powered by agentic AI, knowledge convergence, and process-as-code. Built on the BlueVerse ecosystem, iRun creates a unified intelligence layer that brings together enterprise data, telemetry, workflows, and operational context—enabling AI to reason across sys
Azafaros to Present at BIO International Convention 202615.6.2026 07:00:00 CEST | Press release
Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A
Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 06:05:00 CEST | Press release
Autonomous launch, recovery, and recharge from military vehicles and fixed installations; Three-drone rotation provides persistent surveillance and real-time targeting data in contested environments Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integrati
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom